Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer

Recruiting now

Conditions studied: Cancer of Cervix, Apoptosis

In brief

Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.

Key facts

Study ID

NCT06147960

Run by

Centre Hospitalier Universitaire de Nīmes

People needed

180

Starts

2024-09-26

Expected to finish

2027-11-01

Last updated by the study team

2026-06-22

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients treated with the exclusive radio-chemotherapy combination for locally advanced cervical carcinoma (stage Ib-IVb according to FIGO classification).
• Patients aged ≥ 18 years.
• Patients with a minimum of 2 years post-treatment follow-up.
• Patients for whom the initial biopsy specimen (before treatment) is available.
• Patients who have not indicated that they do not wish to participate in the study.
• Patients affiliated to or benefiting from a health insurance scheme.

You may not qualify if…

• Patients under court protection, guardianship or curatorship.

Where it is running

• CHU de Nîmes — Nîmes, Gard, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.